Are Patients Underprotected ?
Booster vaccination rates among older adolescents are low1
It is estimated that approximately 6 million adolescents 16-18 years of age have not been vaccinated with a booster dose, leaving them underprotected.2
Determine your practice’s booster rate
- Compare the numbers of younger and older adolescent patients in your practice with the amount of Menactra vaccine you order
- Comb through your electronic medical records (EMRs) for undervaccinated 16- through 18-year-old patients and flag them for follow-up
- Implement a protocol to check every older adolescent’s chart and flag those who have not received a booster dose
Even 1 underprotected patient is too many
Identify booster vaccination opportunities in your practice
- Establish a consistent booster immunization protocol for every health care provider in your office to follow
- Remember that a large number of US adolescents may not go to college, meaning that they are less likely to come in for a meningococcal vaccination
- Consider implementing patient outreach tactics such as use of recall scripts, reminder postcards, and questionnaires at sign-in
IMPORTANT SAFETY INFORMATION FOR MENACTRA VACCINE
Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine.
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.
The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.
INDICATION FOR MENACTRA VACCINE
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Before administering Menactra vaccine, please see accompanying full Prescribing Information.
- 1. Centers for Disease Control and Prevention. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2015. MMWR. 2016;65(33):850-858. 2. Sanofi Pasteur Inc. Data on File (2nd Dose immunization rates). February 2017. MKT32188.